Sep 17, 2020 Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
Sep 10, 2020 Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences
Aug 17, 2020 Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020
Aug 05, 2020 Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
Jul 27, 2020 Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020
May 06, 2020 Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
Apr 21, 2020 Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab
Mar 11, 2020 Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights